Results 61 to 70 of about 112 (79)

Effect of Treatment with Mucoactive Drugs on COPD Exacerbations During 5 years of Follow-up in the Czech Republic: A Real-World Study. [PDF]

Lung
Zatloukal J, Page C, Brat K, Svoboda M, Voláková E, Plutinský M, Kopecký M, Koblížek V.   +7 more
europepmc   +1 more source

Management of airway mucus hypersecretion in chronic airway inflammatory disease: Chinese expert consensus (English edition). [PDF]

Int J Chron Obstruct Pulmon Dis, 2018
Shen Y, Huang S, Kang J, Lin J, Lai K, Sun Y, Xiao W, Yang L, Yao W, Cai S, Huang K, Wen F.   +11 more
europepmc   +1 more source

Synergistic action of mucoactive drugs and phages against <i>Pseudomonas aeruginosa</i> and <i>Klebsiella pneumoniae</i>. [PDF]

Microbiol Spectr
Sui B, Li X, Li N, Tao Y, Wang L, Xu Y, Hou Y, Hu B, Tan D.   +8 more
europepmc   +1 more source

Revised (2018) COPD Clinical Practice Guideline of the Korean Academy of Tuberculosis and Respiratory Disease: A Summary. [PDF]

Tuberc Respir Dis (Seoul), 2018
Park YB, Rhee CK, Yoon HK, Oh YM, Lim SY, Lee JH, Yoo KH, Ahn JH, Committee of the Korean COPD Guideline 2018.   +8 more
europepmc   +1 more source

Effects of Morus alba L. and Natural Products Including Morusin on In Vivo Secretion and In Vitro Production of Airway MUC5AC Mucin. [PDF]

Tuberc Respir Dis (Seoul), 2014
Lee HJ, Ryu J, Park SH, Woo ER, Kim AR, Lee SK, Kim YS, Kim JO, Hong JH, Lee CJ.   +9 more
europepmc   +1 more source

Mucoactive Agents in Muco-Obstructive Lung Diseases: A Critical Reappraisal of Pharmacological Effects and Clinical Outcomes. [PDF]

Pharmaceuticals (Basel)
Larobina D, Franzino G, Tescione F, Abrami M, Tierno D, Biasin A, Tonon F, De Nes A, Maggisano M, Confalonieri P, Carbone A, Confalonieri M, Grassi G, Di Gioia S, Grassi M, Conese M.   +15 more
europepmc   +1 more source

Mucoactive and antioxidant medicines for COPD: consensus of a group of Chinese pulmonary physicians. [PDF]

Int J Chron Obstruct Pulmon Dis, 2017
Yan X, Song Y, Shen C, Xu W, Chen L, Zhang J, Liu H, Huang M, Lai G, Qian G, Wang J, Ye X, Zheng J, Bai C.   +13 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Modulating effects of mucoregulating drugs on the attachment of Haemophilus influenzae

Microbial Pathogenesis, 2001
Non-typable Haemophilus influenzae (NTHI) is one of the three major pathogens implicated in human respiratory infections. The ability to attach with pharyngeal epithelial cells is an important factor for infection and virulence. In the present study we describe the effects of two mucoregulating drugs, S-carboxymethylcysteine (S-CMC) and ambroxol, on ...
C T, Ndour, K, Ahmed, T, Nakagawa, Y, Nakano, A, Ichinose, G, Tarhan, M, Aikawa, T, Nagatake   +7 more
openaire   +2 more sources

Effect of the mucoregulator S-carboxy-methyl-cysteine in patients with chronic bronchitis

European Journal of Clinical Pharmacology, 1978
Twenty patients with stable chronic bronchitis entered a double-blind study in which changes in clinical and respiratory function and biochemical and rheological variations were examined after treatment with the mucoregulator S-carboxy-methyl-cysteine (S.C.M.C.).
E, Puchelle, F, Aug, J M, Polu
openaire   +2 more sources

Reduced Airway Inflammation and Remodeling in Parallel with Mucin 5AC Protein Expression Decreased by S-Carboxymethylcysteine, a Mucoregulant, in the Airways of Rats Exposed to Sulfur Dioxide

International Archives of Allergy and Immunology, 2004
<i>Background:</i> Human obstructive airway diseases are histopathologically characterized by inflammatory cell infiltration, goblet cell hyperplasia, and mucus hypersecretion in airways. We prepared a rat model of airway injury by exposure of sulfur dioxide (SO₂) and then evaluated the effects of S ...
Sumihisa, Sueyoshi, Yuki, Miyata, Yoshihiro, Masumoto, Yuji, Ishibashi, Shigeki, Matsuzawa, Naoki, Harano, Kiyoyuki, Tsuru, Shigeru, Imai   +7 more
openaire   +2 more sources